Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck/Pfizer's Latest SGLT-2 Data Support Attractive Ertugliflozin/Januvia Combo

Executive Summary

Overall, data suggest a profile similar to J&J's market-leading Invokana, but analysts still see room for a new entrant to the anti-SGLT-2 class in type 2 diabetes.

Advertisement

Related Content

Merck: As The Sun Rises For Keytruda, It Sets For Zetia/Vytorin
Invokana, Farxiga New Safety Warning May Give Jardiance Market Edge
ADA: Diabetes Duo Merck & Pfizer Report Positive PhIII Data For Investigational SGLT-2
Januvia Gains Another Boost With FDA Warnings for Onglyza, Nesina

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC097303

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel